According to this study, the global siRNA Drugs market size will reach US$ million by 2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of siRNA Drugs market by product type, application, key players and key regions and countries.
Segmentation by product type:
Without GalNAc-conjugated
With GalNAc-conjugated
Segmentation by Application:
Genetic Disease
Cancers
Other
This report also splits the market by region:
United States
China
Europe
Other regions:
Japan
South Korea
Southeast Asia
Rest of world
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:
Alnylam
Novartis
Sirnaomics
Ribo Life Science
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global siRNA Drugs 麻豆原创 Size 2024-2030
2.1.2 siRNA Drugs 麻豆原创 Size CAGR by Region
2.2 siRNA Drugs Segment by Type
2.2.1 Without GalNAc-conjugated
2.2.2 With GalNAc-conjugated
2.3 siRNA Drugs 麻豆原创 Size by Type
2.3.1 Global siRNA Drugs 麻豆原创 Size 麻豆原创 Share by Type (2024-2030)
2.3.2 Global siRNA Drugs 麻豆原创 Size Growth Rate by Type (2024-2030)
2.4 siRNA Drugs Segment by Application
2.4.1 Genetic Disease
2.4.2 Cancers
2.4.3 Other
2.5 siRNA Drugs 麻豆原创 Size by Application
2.5.1 Global siRNA Drugs 麻豆原创 Size 麻豆原创 Share by Application (2024-2030)
2.5.2 Global siRNA Drugs 麻豆原创 Size Growth Rate by Application (2024-2030)
3 siRNA Drugs Key Players
3.1 Date of Key Players Enter into siRNA Drugs
3.2 Key Players siRNA Drugs Product Offered
3.3 Key Players siRNA Drugs Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players siRNA Drugs Valuation & 麻豆原创 Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 麻豆原创 Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 siRNA Drugs by Regions
4.1 siRNA Drugs 麻豆原创 Size by Regions (2024-2030)
4.2 United States siRNA Drugs 麻豆原创 Size Growth (2024-2030)
4.3 China siRNA Drugs 麻豆原创 Size Growth (2024-2030)
4.4 Europe siRNA Drugs 麻豆原创 Size Growth (2024-2030)
4.5 Rest of World siRNA Drugs 麻豆原创 Size Growth (2024-2030)
5 United States
5.1 United States siRNA Drugs 麻豆原创 Size by Type (2024-2030)
5.2 United States siRNA Drugs 麻豆原创 Size by Application (2024-2030)
6 Europe
6.1 Europe siRNA Drugs 麻豆原创 Size by Type (2024-2030)
6.2 Europe siRNA Drugs 麻豆原创 Size by Application (2024-2030)
7 China
7.1 China siRNA Drugs 麻豆原创 Size by Type (2024-2030)
7.2 China siRNA Drugs 麻豆原创 Size by Application (2024-2030)
8 Rest of World
8.1 Rest of World siRNA Drugs 麻豆原创 Size by Type (2024-2030)
8.2 Rest of World siRNA Drugs 麻豆原创 Size by Application (2024-2030)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Key Investors in siRNA Drugs
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and 麻豆原创 Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and 麻豆原创 Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and 麻豆原创 Layout
10.4 Company D
10.5 鈥︹��
11 Key Players Analysis
11.1 Alnylam
11.1.1 Alnylam Company Details
11.1.2 Alnylam siRNA Drugs Product Offered
11.1.3 Alnylam siRNA Drugs 麻豆原创 Size (2024 VS 2030)
11.1.4 Alnylam Main Business Overview
11.1.5 Alnylam News
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis siRNA Drugs Product Offered
11.2.3 Novartis siRNA Drugs 麻豆原创 Size (2024 VS 2030)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis News
11.3 Sirnaomics
11.3.1 Sirnaomics Company Details
11.3.2 Sirnaomics siRNA Drugs Product Offered
11.3.3 Sirnaomics siRNA Drugs 麻豆原创 Size (2024 VS 2030)
11.3.4 Sirnaomics Main Business Overview
11.3.5 Sirnaomics News
11.4 Ribo Life Science
11.4.1 Ribo Life Science Company Details
11.4.2 Ribo Life Science siRNA Drugs Product Offered
11.4.3 Ribo Life Science siRNA Drugs 麻豆原创 Size (2024 VS 2030)
11.4.4 Ribo Life Science Main Business Overview
11.4.5 Ribo Life Science News
...
12 Research Findings and Conclusion
听
听
*If Applicable.
